Are Alternative Distribution Models a Viable Option for Pharma?
The key questions and considerations for drug manufacturers pursuing an effective Alternative Distribution Model.
Pharmaceutical Commerce engaged Rob Besse from Archbow Consulting to walk the industry through the three essential factors manufacturers must contemplate when considering an ADM.
Read Rob’s article in Pharmaceutical Commerce and contact us if we can be of assistance in helping you resolve your distribution challenges. As a pharmaceutical consulting company, Archbow provides strategic guidance and tactical implementation support for various distribution areas, including wholesale, specialty distribution, and 3PL services.
For additional insights on this topic, you may also enjoy the following:
Archbow Consulting helps pharmaceutical and biotech companies in the USA and Europe design, build, and optimize product distribution and patient access strategies. Archbow was founded by industry veterans to meet a need in the marketplace for consulting options that offer diverse real-world experience, are able to leverage deep connections across the industry, and can also provide actionable strategic guidance. We invite you to learn more about our team, services, and clients’ success, and connect with us via email, LinkedIn or subscribing to this blog which you can do below.
Share in
Recent Posts
Revolutionizing Patient Care: The Top 5 Benefits of Investing in Innovation
Why manufacturers must embrace innovative trends to stay ahead
FDA Extends Compliance Deadline for Updated DSCSA Requirements
Understanding the revised timeline for compliance with specific updated DSCSA requirements
Are Direct-to-Patient Access Models the Future of Pharma?
Understanding the opportunity to sell directly to patients via a cash model
SUBSCRIBE
Subscribe to receive news and updates from Archbow Consulting
|